Trial Profile

Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pralatrexate (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Spectrum Pharmaceuticals

Most Recent Events

07 Jul 2012 Planned number of patients changed from 30 to 78 as reported by European Clinical Trials Database.(Parent trial: EudraCT2008-006425-14).
07 Jul 2012 Planned number of patients changed from 30 to 78 as reported by European Clinical Trials Database.(Parent trial: EudraCT2008-006425-14).
09 Jun 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database (Extension trial: EudraCT2011-001309-29).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com